Redefining hydrophilic coatings solutions by uniting advanced chemistry, device engineering and customer-first partnerships BEVERLY, Mass.–(BUSINESS WIRE)–#FreudenbergRedefining hydrophilic coatings solutions by uniting advanced chemistry, device engineering and customer-first partnerships BEVERLY, Mass.–(BUSINESS WIRE)–#Freudenberg

Freudenberg Medical Ushers in a New Era for Hydrophilic Coatings with Launch of LUBRITEQ™

5 min read

Redefining hydrophilic coatings solutions by uniting advanced chemistry, device engineering and customer-first partnerships

BEVERLY, Mass.–(BUSINESS WIRE)–#Freudenberg—Freudenberg Medical, a global contract design and manufacturing (CDMO) partner to the medical device and biopharma industry, today announced the launch of LUBRITEQ™, a new high-performance hydrophilic coating solution, along with a comprehensive suite of associated development and manufacturing services. LUBRITEQ™ is now available globally across Freudenberg Medical’s vertically integrated operations.

With the launch of LUBRITEQ™, Freudenberg Medical becomes the only hydrophilic coating provider to unite advanced surface chemistry with deep, in-house medical device design and manufacturing capabilities—bringing together complementary technologies to enhance manufacturability and deliver greater productivity and reliability across the entire product development lifecycle.

“Hydrophilic coatings and device design must work in perfect harmony to deliver optimal performance, yet the industry has traditionally approached them as separate disciplines,” said Michael McGee, CEO of Freudenberg Medical. “As a uniquely integrated technical partner, we enable customers to move faster, with less risk and greater confidence, by combining product design, advanced materials, precision coatings, and application expertise for seamless development, scale-up, and launch.”

Built on a Deep Expertise in Surface Chemistry

Freudenberg Medical brings more than 25 years of experience in coating science, supported by a proven legacy of innovation, including expertise integrated through Hemoteq, that has enabled customers to achieve multiple industry firsts in complex drug-device and surface modification solutions.

“With more than 40 coating scientists, chemical engineers and technicians working alongside 250 medical device & catheter engineers globally, we have unparalleled expertise in developing complex chemistry and drug-device solutions for our customers,” said McGee. “We already support over one million medical devices each year for functional surface coatings, making the introduction of LUBRITEQ™, our hydrophilic coating solution, a natural evolution and logical next step aligned with our customers’ needs.”

Shaped by Customer Needs

Freudenberg Medical’s decision to enter the hydrophilic coatings market was guided by extensive engagement with customers and industry stakeholders to understand where existing solutions and partnerships can be improved, and where unmet needs continue to exist. Through these exchanges, it became clear that while coating technologies have advanced, customer needs are not being fully served—particularly when it comes to the flexibility of support services and complexities of royalties, licenses and fees.

“We heard consistent feedback that directly shaped our strategy,” said Freudenberg Medical’s Chief Commercial Officer, Keith Kiernan. “Customers aren’t just looking for a better coating—they’re looking for a better partner to de-risk their product launches. We deliberately set out to deliver a solution—and a partnership model—that reflects exactly what customers told us they need. No royalties, no rigidity—just coating performance, partnership and progress.”

Introducing LUBRITEQ™ Hydrophilic Coating & Services

LUBRITEQ™ is an advanced, UV-curable, single-step hydrophilic coating engineered for versatility and performance across a wide range of medical device applications and polymer & metal substrates. The coating delivers high lubricity with exceptional durability, consistent uniformity and ultra-low particulates. LUBRITEQ™ is customizable to optimize performance for specific device requirements and is compatible with virtually all approved materials used in medical device designs.

Recognizing that coating performance alone is not enough, Freudenberg Medical is launching LUBRITEQ™ alongside a comprehensive services model that supports customers across the full product lifecycle—from early feasibility through commercial production. Services include a rapid two-week first feasibility turnaround, tailored coating customization programs, and flexible volume-manufacturing options, including process transfer to the customer or contract coating support across Freudenberg Medical’s global site network. This integrated approach eliminates hand-offs across multiple suppliers, reducing risk and accelerating product development timelines.

Customer-First and Transparent, Commercial Model

In contrast to traditional industry practices, Freudenberg Medical is introducing a straightforward and transparent commercial model for LUBRITEQ™, designed to eliminate hidden costs and reduce program launch risk. Customers can access a high-performance hydrophilic coating solution with no royalties, no fixed or annual fees, and no regulatory file access fees.

Together, these elements remove commercial barriers and enable long-term, trust-based partnerships.

“With LUBRITEQ™, Freudenberg Medical is raising the bar for what a hydrophilic coating partner can and should be,” said CEO Michael McGee. “The early responses we’re seeing from customers confirm that we’re meeting a real need. Great technology, great service and a commercial model built on trust—that’s the standard we are setting.”

Freudenberg Medical is launching LUBRITEQ™ at MD&M West. Visit Booth 2609 to learn more about LUBRITEQ™ and discover how Freudenberg Medical is redefining what’s possible in hydrophilic coatings. Visit LUBRITEQ™ for more information.

About Freudenberg Medical

Freudenberg Medical is a trusted strategic CDMO partner to medical device and pharmaceutical companies, committed to delivering high-quality solutions from ideation to market launch and volume production. With over 2,900 associates across 12 global manufacturing sites in key MedTech hubs and proven expertise in materials and technologies, Freudenberg Medical offers an extensive range of vertically integrated capabilities: from minimally invasive solutions including complex catheters, hypotubes, steerable shafts, handles as well as drug and hydrophilic coatings to precision molding, two-shot and micro molding, advanced extrusions, and solutions for smart medical devices. www.freudenbergmedical.com

Contacts

Media Contacts
Laura Kirstein
Director Marketing and Communications
Freudenberg Medical
[email protected]

Maura Leahy
Strategic Marketing
Freudenberg Medical
[email protected]

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Wormhole launches reserve tying protocol revenue to token

Wormhole launches reserve tying protocol revenue to token

The post Wormhole launches reserve tying protocol revenue to token appeared on BitcoinEthereumNews.com. Wormhole is changing how its W token works by creating a new reserve designed to hold value for the long term. Announced on Wednesday, the Wormhole Reserve will collect onchain and offchain revenues and other value generated across the protocol and its applications (including Portal) and accumulate them into W, locking the tokens within the reserve. The reserve is part of a broader update called W 2.0. Other changes include a 4% targeted base yield for tokenholders who stake and take part in governance. While staking rewards will vary, Wormhole said active users of ecosystem apps can earn boosted yields through features like Portal Earn. The team stressed that no new tokens are being minted; rewards come from existing supply and protocol revenues, keeping the cap fixed at 10 billion. Wormhole is also overhauling its token release schedule. Instead of releasing large amounts of W at once under the old “cliff” model, the network will shift to steady, bi-weekly unlocks starting October 3, 2025. The aim is to avoid sharp periods of selling pressure and create a more predictable environment for investors. Lockups for some groups, including validators and investors, will extend an additional six months, until October 2028. Core contributor tokens remain under longer contractual time locks. Wormhole launched in 2020 as a cross-chain bridge and now connects more than 40 blockchains. The W token powers governance and staking, with a capped supply of 10 billion. By redirecting fees and revenues into the new reserve, Wormhole is betting that its token can maintain value as demand for moving assets and data between chains grows. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/wormhole-launches-reserve
Share
BitcoinEthereumNews2025/09/18 01:55
Kalshi debuts ecosystem hub with Solana and Base

Kalshi debuts ecosystem hub with Solana and Base

The post Kalshi debuts ecosystem hub with Solana and Base appeared on BitcoinEthereumNews.com. Kalshi, the US-regulated prediction market exchange, rolled out a new program on Wednesday called KalshiEco Hub. The initiative, developed in partnership with Solana and Coinbase-backed Base, is designed to attract builders, traders, and content creators to a growing ecosystem around prediction markets. By combining its regulatory footing with crypto-native infrastructure, Kalshi said it is aiming to become a bridge between traditional finance and onchain innovation. The hub offers grants, technical assistance, and marketing support to selected projects. Kalshi also announced that it will support native deposits of Solana’s SOL token and USDC stablecoin, making it easier for users already active in crypto to participate directly. Early collaborators include Kalshinomics, a dashboard for market analytics, and Verso, which is building professional-grade tools for market discovery and execution. Other partners, such as Caddy, are exploring ways to expand retail-facing trading experiences. Kalshi’s move to embrace blockchain partnerships comes at a time when prediction markets are drawing fresh attention for their ability to capture sentiment around elections, economic policy, and cultural events. Competitor Polymarket recently acquired QCEX — a derivatives exchange with a CFTC license — to pave its way back into US operations under regulatory compliance. At the same time, platforms like PredictIt continue to push for a clearer regulatory footing. The legal terrain remains complex, with some states issuing cease-and-desist orders over whether these event contracts count as gambling, not finance. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/kalshi-ecosystem-hub-solana-base
Share
BitcoinEthereumNews2025/09/18 04:40
Optimizely Named a Leader in the 2026 Gartner® Magic Quadrant™ for Personalization Engines

Optimizely Named a Leader in the 2026 Gartner® Magic Quadrant™ for Personalization Engines

Company recognized as a Leader for the second consecutive year NEW YORK, Feb. 5, 2026 /PRNewswire/ — Optimizely, the leading digital experience platform (DXP) provider
Share
AI Journal2026/02/06 00:47